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Background: Based on age of presentation, celiac disease (CD) is categorised as pediatric CD and adult CD. It
however remains unclear if these are genetically and/or phenotypically distinct disorders or just different spectrum
of the same disease. We therefore explored the common genetic components underlying pediatric and adult CD in
a well characterized north Indian cohort.
Methods: A retrospective analysis of children (n = 531) and adult (n = 871) patients with CD between January 2001
and December 2010 was done. The database included basic demographic characteristics, clinical presentations,
associated diseases and complications, if any. The genotype dataset was acquired for children (n = 217) and adult
CD patients (n = 340) and controls (n = 736) using Immunochip. Association analysis was performed using logistic
regression model to identify susceptibility genetic variants.
Results: The predominant form of CD was classical CD in both pediatric and adult CD groups. There was
remarkable similarity between pediatric and adult CD except for quantitative differences between the two groups
such as female preponderance, non-classical presentation, co-occurrence of other autoimmune diseases being
more common amongst adult CD. Notably, same HLA-DQ2 and –DQ8 haplotypes were established as the major
risk factors in both types of CD. In addition, a few suggestively associated (p < 5 × 10−4) non-HLA markers were
identified of which only ANK3 (rs4948256-A; rs10994257-T) was found to be shared and explain risk for ~45 % of CD
patients with HLA allele.
Discussion: Overall phenotypic similarity between pediatric and adult CD groups can be explained by contribution
of same HLA risk alleles. Different non-HLA genes/loci with minor risk seem to play crucial role in disease onset and
extra intestinal manifestation of CD. None of the non-HLA risk variants reached genome-wide significance, however
most of them were shown to have functional implication to disease pathogenesis. Functional relevance of our
findings needs to be investigated to address clinical heterogeneity of CD.
Conclusions: This present study is the first comparative study based on common genetic markers to suggest that
CD in pediatric age group and in adults are the spectrum of the same disease with novel and shared genetic risk
determinants. Follow-up fine mapping studies with larger study cohorts are warranted for further genetic
investigation.
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Celiac disease (CD) is a chronic systemic inflammatory
condition of autoimmune origin as a result of permanent
intolerance to gluten in genetically predisposed individ-
uals [1, 2]. CD was thought initially to be a disease of
children and was treated mainly by pediatricians. Over
past two decades, it was realized that CD also occurs in
adults [3, 4]. Such observations led to the concept of
pediatric CD and adult onset CD and it’s sub-
clasification based on the age at disease diagnosis [5, 6].
Pediatric CD develops in early years of life with intro-
duction of gluten containing cereals in their diets and
presents mostly with classical features of CD such as
chronic diarrhoea, abdominal distension, failure to thrive
and deficiencies of nutrients. On the other hand, adult
CD presents later in life and has both classic manifesta-
tions and non-classical manifestation such as fatigue, an-
aemia, bone disease, idiopathic seizures, cryptogenic
liver disease and various autoimmune diseases [7, 8].
The past two decades have witnessed considerable ef-
forts to unravel the pathogenesis of CD including gen-
etic risk determinants [9, 10]. HLA-DQ2 and -DQ8
haplotypes have been the most consistently reported
genetic markers conferring ~40 % risk for CD develop-
ment [11, 12]. More recently, an additional 39 loci have
been identified by genome-wide association studies
(GWAS) and Immunochip based genetic analysis [13].
These additional loci are estimated to confer an add-
itional ~15 % genetic risk to them and explained ~55 %
of the CD cases [12]. While all these genetic and clinical
studies have brought extremely important information,
they however have not delineated phenotypic and gen-
etic characteristics based on the age at the onset leaving
significant gaps in our understanding of these two dis-
tinct categories. We therefore explored the genetic land-
scape of a well characterized cohort of pediatric CD and
adult CD.
Our observations are suggestive of novel as well as mod-
erately shared genetic determinants underlying these two
distinct celiac disease groups.
Methods
Study cohort
Database registry system for patients with CD being
maintained at the Gastroenterology Department, Daya-
nand Medical College and Hospital since 1995, was used
in this study. A patient registry database containing de-
tailed baseline and follow up clinical and laboratory
characteristics of all the patients with confirmed diagno-
sis of CD.
A retrospective database analysis of all the patients
(n = 1402) with CD between January 2001 and December
2010 was done. The diagnosis of CD was established as
per modified ESPGHAN criteria [14, 15]. Approval forthis study was obtained from Institutional Ethics Commit-
tee (IEC) of University of Delhi South Campus, New Delhi
and Drug Trial Ethics Committee (DTEC), Dayanand
Medical College and Hospital, Ludhiana. An informed
and written consent was obtained from all the partici-
pants. The baseline demographic characteristics such as
age at the diagnosis, gender of the participants, and dur-
ation of the symptoms prior to diagnosis of CD was
retrived from the database. Patients ≥18 years of age at
diagnosis were identified as adult CD while patients
<18 years were identified as having pediatric CD. Recruit-
ment of pediatric CD patients were guided by “Conven-
tion on the Rights of the Child” adopted by the United
Nations General Assembly (1989) and Indian Association
of Pediatric Policy Statement on Age of Children for
Pediatric Care (1999). Patients presenting symptoms such
as chronic diarrhea, malabsorption and failure to thrive
were classified as Classical CD and those presenting as
extra intestinal manifestations such as short stature, fa-
tigue, iron deficiency anaemia, osteoporosis, delayed pu-
berty, infertility, cryptogenic chronic liver disease,
idiopathic seizure and dyspepsia not responding to PPI
were classified as non-classical CD. Subjects detected to
have CD on screening of high-risk group such as family
members of index patient, type I diabetes mellitus, crypto-
genic liver disease, infertility, thyroiditis were classified as
“Screen detected’ [15].
Relevant laboratory data including baseline haemoglo-
bin and anti-tTG antibody levels were recorded. All the
patients had undergone gastroduodenoscopic examin-
ation and their duodenal biopsies obtained. The grade of
villous atrophy was classified as per modified Marsh cri-
teria [16, 17]. All study subjects were from the north
part of India and had been residents of the state of Pun-
jab, a State in Northern part of India, for more than
three generations.
Genetic analysis
Of the 1402 CD patients, 557 patients (n = 217 pediatric
CD and n = 340 adult CD) were available for genetic
analysis and their DNA was genotyped on the Illumina
immunochip genotyping platform [13]. Unrelated
healthy blood donors (n = 736) from the same locality
and community having anti-tTG antibody value within
normal range were recruited as controls. They were also
genotyped on the Illumina immunochip genotyping plat-
form. The controls were common for both the adults
and pediatric patients with CD.
DNA from peripheral whole blood was extracted using
conventional phenol-chloroform method at University of
Delhi, South Campus, New Delhi, India. Samples were
hybridized on the Immunochip platform at the genotyp-
ing facility, University Medical Centre Groningen, The
Netherlands, as a part of the Celiac Disease Consortium
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~186 known immune loci densely covered with 196524
polymorphic variants described before [13, 18]. Total
sample set was divided into two groups namely i)
Pediatric CD (n = 217); and ii) Adult CD (n = 340). All
the quality control steps, as described elsewhere [13, 18]
were performed separately on these two groups. Add-
itionally, all markers with minor allele frequency (MAF)
<0.10 were removed. After stringent QC, datasets for
Pediatric CD and Adult CD were analysed separately for
test of association. Principal component analysis (PCA)
was performed using markers in linkage equilibrium
(LD < 0.10) to elucidate the underlying genetic stratifica-
tion present in the study cohort. Principal components 1
to 4 were included as covariates to correct for popula-
tion stratification and genomic inflation. Since, multiple
markers were tested for association in this study (similar
to genome-wide association studies), to avoid false posi-
tives, Bonferroni correction was applied. Accordingly,
significance level was kept at p ≤5 × 10−7 level and sug-
gestive association at p-values between 5 × 10−7 and 5 ×
10−4. Genetic heterogeneity of odds ratio obtained in test
of association (described above) between Pediatric CD
and Adult CD were tested using Breslow-Day statistics.
Identified variants were further analysed in silico for
their functional significance by evaluating their expres-
sion effects (cis-eQTL) on neighbouring genes. Genome-
wide whole blood expression data was used, given in
Blood eQTL browser [19] to identify cis-eQTL effect of
the variants. Further, we used GRAIL (Gene Relation-
ships Across Implicated Loci) [20] to understand the
possible relationships of the genes identified in our study
with already known genes at 39 non-HLA CD loci [13].
Data availability
Genotyping data for the entire north Indian cohort are
available through the European Genome-Phenome
Archive (http://www.ebi.ac.uk/ega/) with the accession
number EGAS00001000849. The summary statistics can
be obtained by contacting the authors directly.
Results
Clinical characteristics
Of 1402 patients with CD in our database, 531 (37.8 %)
were pediatric CD and 871 (62.2 %) were adult CD. The
mean age at the diagnosis in pediatric CD and adult CD
was 10.08 ± 4.6 years (females 45.4 %) and 35.34 ±
11.83 years (females 60.3 %). The duration of symptoms
before the diagnosis of CD was comparable in adult CD
in comparison to that in pediatric CD (3.31 years versus
2.2 years; p = NS). While the predominant mode of pres-
entation in both pediatric and adult CD was classical
CD; the proportion of patients with classical CD was
higher in pediatric CD in comparison of that in adultCD (75.5 % vs 69.6 %; p = 0.009). The non-classical pres-
entation was statistically higher in adult CD in compari-
son to that in pediatric CD (20.3 % vs 25.2 %; p = 0.02).
Iron deficiency anemia and hypothyroidism were more
commonly reported in adult CD (Table 1). Complica-
tions such as celiac crisis, refractory sprue and associ-
ated malignancy were seen in the adult group. The
various malignancies reported included oesophageal,
colon, stomach and small bowel sarcoma (one each).
Dermatitis herpetiformis was seen in 3 adult CD cases
while none was observed in pediatric CD. Associated
autoimmune disorders, investigations, titre of anti-tTG
antibody in pediatric and adult CD are summarized in
Table 1.
Genetic analysis
After stringent quality control of the immunochip based
genotype data, a total of 27 pediatric CD, 33 adult CD
and 6 controls were removed. Following removal of
poorly clustered markers due to poor hybridization,
172,242 markers were considered for further analysis. Of
them, 88,776 and 88,793 markers in Pediatric CD and
Adult CD groups passed the QC steps. The genomic con-
trol inflation factor of association test statistics (λGC) was
observed to be very limited in the two groups analysed in
the study (λGC = 1.11 for pediatric CD; and λGC = 1.01 for
adult CD) (Additional file 1: Figure S1a and b). Notably,
Pediatric CD and Adult CD had 90 % and 95 % power, re-
spectively to detect association of a variant having minor
allele frequency (MAF) >0.20 and odds ratio (OR) >1.50.
Test of association
HLA locus emerged as the most significantly associated
marker both in pediatric and adult CD patients (Tables 2
and 3; Additional file 1: Figure S2a and b). The strongest
signal was at rs2854275, G > T, which is localized in the
last intron of HLA-DQB1and which is in very strong LD
(r2 = 0.95, D’ = 1) with European top HLA marker
rs2187668 from HLA-DQA1, was common in both
pediatric CD (p = 4.28 × 10−29) and adult CD (p = 5.82 ×
10−35). A frequency of 14.9 % at rs2854275-T allele in
healthy individuals versus 49.7 % in adult CD and 50 %
in pediatric CD patients was noteworthy. Furthermore,
while conditioned on rs2854275, we did not observe any
other genome-wide significant HLA marker in either
pediatric or adult CD groups. Association status of five
known SNPs (rs2395182, rs7775228, rs4713586,
rs2187668 and rs7454108) tagging HLA-DQ haplotypes
[21] were checked in pediatric CD and adult CD. Compar-
able allelic association status for risk alleles (Table 4) and
distribution of different-HLA-DQ haplotypes (Table 5)
were observed between these two groups. We observed
that similar proportion of CD patients in both these
groups (87.30 % in Pediatric CD and 86.97 % in Adult
Table 1 Demographic and clinical characteristics of pediatric and adult celiac disease
Variables Pediatric CD patients (n = 531) Adults CD patients (n = 871) P value









































































































Mean titre of anti-tTG antibody (U/L) 130.00 118.60 1 × 10−3

















NA not applicable, The values presented in parenthesis is a percentages
Bolds (P values) are the significant associations (p ≤ 0.05)
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DQ2.5 or -DQ8, which was also comparable that reported
in the European populations [22–24].
On the other hand, 12 distinct non-HLA risk variants
were observed to be suggestively associated (p <5 × 10−4)
with pediatric CD and 19 variants with adult CD with
only ANK3 gene being common to both groups (Tables 2
and 3). Though most of these are suggestive associations
for CD, a few of them are known risk loci for other im-
mune disorders (Additional file 2: Table S1). Except for
ANK3 [ankyrin 3], ARHGAP39 [Rho GTPase activat-
ing protein 39], LILRA3 [leukocyte immunoglobulin-
like receptor, superfamily A (without TM domain),
member 3] and CSGALNACT1 (chondroitin sulfate
N-acetylgalactosaminyltransferase 1] other Pediatric CD
specific loci were not replicated (p ≤ 0.05) in Adult CD.
Similarly, only four Adult CD specific loci, namely VAV2[vav 2 guanine nucleotide exchange factor], FAM181B
[family with sequence similarity 181, member B], non-
genic region at 5p15.33, ANK3 [ankyrin 3] and ITLN2
[intelectin 2] were replicated in pediatric CD. Further
~58 % Pediatric CD specific variants were heterogeneous
(p_BD < 0.05) compared to ~26 % among adult CD spe-
cific variants (Additional file 2: Table S2). cis-eQTL ana-
lysis revealed five variants in the Pediatric CD group and
six in the Adult CD group to be functionally relevant
(Additional file 2: Table S3). GRAIL analysis revealed
three loci, two from Pediatric CD and one from Adult CD
to be significantly connected with the known 39 non-HLA
CD loci (Additional file 2: Table S4).
Discussion
Celiac disease is one of the complex disorder where the
major non-genetic factor namely gluten has been very
Table 2 Top association signals identified in Pediatric CD and their association status in Adult CD among north Indians patients
Pediatric CD Adult CD
SNPs (RA) RAF OR P OR P Position Ref Seq genes
rs2854275 T 0.15 6.22[4.52–8.57] 4.28 × 10−29 6.11[4.58–8.15] 5.82 × 10−35 intronic HLA-DQB1
rs4948256 A 0.22 1.90[1.46–2.48] 2.06 × 10−6 1.50[1.18–1.90] 1 × 10−3 intronic ANK3
rs1322423 G 0.87 2.49[1.58–3.94] 8.75 × 10−5 1.05[0.77–1.41] 0.77 694 kb 3’ TSG1
rs4925813 G 0.51 1.64[1.28–2.10] 1.03 × 10−4 1.28[1.04–1.58] 0.02 17 kb 5’ ARHGAP39
rs956506 T 0.23 1.68[1.28–2.20] 1.79 × 10−4 1.20[0.94–1.54] 0.14 intronic MACROD2
rs2981579 C 0.57 1.60[1.25–2.08] 2.54 × 10−4 1.05[0.85–1.29] 0.64 intronic FGFR2
rs4806741 G 0.12 1.84[1.32–2.56] 3.17 × 10−4 1.41[1.03–1.94] 0.03 6.1 kb 5' LILRA3
rs854680 T 0.29 1.58[1.23–2.04] 3.60 × 10−4 1.09[0.87–1.37] 0.45 527 bp 5' CCL16
rs4692386 T 0.50 1.56[1.22–1.99] 3.64 × 10−4 0.93[0.75–1.15] 0.50 189 kb 5' RBPJ
rs9300549 G 0.61 1.64[1.25–2.14] 3.64 × 10−4 0.85[0.68–1.06] 0.16 145 kb 5' GRP183
rs4857943 G 0.29 1.57[1.22–2.01] 3.83 × 10−4 1.20[0.95–1.50] 0.12 178 kb 3' SGOL1
rs10503653 C 0.27 1.60[1.23–2.07] 3.87 × 10−4 1.27[1.01–1.60] 0.05 intronic CSGALNACT1
rs2061737 G 0.51 1.58[1.23–2.03] 3.89 × 10−4 0.91[0.74–1.23] 0.38 3q26.1 N/A
RA risk allele, RAF risk allele frequency in controls
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individuals based on age at onset of the disease have also
been noted. The major limitation to date has however
been the lack of information in the similarities and
differences, if any, in the genetic susceptibility of the
two groups. Analysis of clinical characteristics in thisTable 3 Top association signals identified in Adult CD group and th
Adult CD
SNPs (RA) RAF OR P
rs2854275 T 0.15 6.11[4.58–8.15] 5.82 × 10−35
rs2788057 T 0.44 1.56[1.27–1.92] 2.29 × 10−5
rs11119390 C 0.74 1.72[1.33–2.23] 3.83 × 10−5
rs9359383 G 0.14 1.82[1.37–2.42] 4.05 × 10−5
rs11074015 T 0.45 1.55[1.25–1.92] 7.86 × 10−5
rs422999 C 0.19 1.65[1.29–2.12] 8.21 × 10−5
rs1875897 G 0.57 1.56[1.25–1.95] 1.06 × 10−4
rs2332094 A 0.12 1.79[1.33–2.41] 1.28 × 10−4
rs11220082 C 0.32 1.53[1.23–1.90] 1.38 × 10−4
rs1999594 C 0.33 1.52[1.22–1.88] 1.68 × 10−4
rs1870162 C 0.08 1.85[1.33–2.55] 2.17 × 10−4
rs35164067 A 0.20 1.60[1.25–2.06] 2.28 × 10−4
rs17463487 T 0.65 1.53[1.22–1.92] 2.23 × 10−4
rs6720771 G 0.86 1.73[1.29–2.32] 2.42 × 10−4
rs10141085 G 0.18 1.62[1.25–2.10] 2.44 × 10−4
rs4897233 G 0.40 1.49[1.20–1.84] 2.50 × 10−4
rs1399357 C 0.51 1.49[1.20–1.85] 2.56 × 10−4
rs963872 C 0.42 1.48[1.19–1.83] 3.38 × 10−4
rs10994257 T 0.26 1.51[1.20–1.90] 4.00 × 10−4
rs12730072 T 0.09 1.76[1.29–2.41] 4.10 × 10−4
RA risk allele, RAF risk allele frequency in controlsstudy cohort has demonstrated that while classic CD
is the predominant manifestation in both pediatric
and adult CD, non-classical manifestations are also
commonly present in both the groups, iron deficiency
anaemia being the most frequent (Table 1). An associ-
ation has been reported between other autoimmuneeir association status in Pediatric CD among north Indians
Pediatric CD
OR P Position Ref Seq genes
6.22[4.52–8.57] 4.28 × 10−29 intronic HLA-DQB1
1.20[0.95–1.53] 0.13 intronic NMNAT2
1.14[0.86–1.49] 0.36 intronic MAPKAPK2
1.39[0.99–1.94] 0.06 12 kb 5’ LCA5
1.01[0.80–1.28] 0.93 126.6 kb 5' SLCO3A1
1.34[1.00–1.78] 0.05 intronic VAV2
1.17[0.91–1.50] 0.22 intronic CSMD1
1.27[0.88–1.82] 0.20 8.6 kb 5' KIAA0247
1.04[0.81–1.35] 0.76 intronic FEZ1
1.11[0.86–1.43] 0.40 20.4 kb 3' KIAA2013
N/A N/A intronic GRID1
1.23[0.92–1.65] 0.17 6.1 kb 5' PDE4A
1.10[0.85–1.41] 0.47 131.6 kb 3' ZNF326
1.16[0.85–1.59] 0.34 intronic GALNT13
0.95[0.69–1.31] 0.77 intronic KIAA0391
1.24[0.97–1.58] 0.09 intronic THEMIS
1.29[1.01–1.64] 0.04 363 kb 3' FAM181B
1.32[1.03–1.69] 0.03 5p15.33 N/A
1.62[1.25–2.09] 2.48 × 10−4 intronic ANK3
1.67[1.14–2.42] 8 × 10−3 229 bp 5' ITLN2




Risk allele frequency P-value OR CD
groupsIndian African European
HLA-DQ2.2 (rs2395182) T 0.83 0.73 0.76 1.06 × 10−5 2.72 [1.74–4.25] Pediatric
6.26 × 10−5 1.99 [1.42–2.79] Adult
HLA-DQ2.2 (rs7775228) T 0.73 0.83 0.85 1.14 × 10−4 1.89 [1.36–2.63] Pediatric
5.08 × 10−7 2.12 [1.58–2.84] Adult
HLA-DQ2.5 (rs2187668) A 0.16 0.06 0.10 3.46 × 10−28 6.03 [4.38–8.30] Pediatric
2.45 × 10−34 5.99 [4.49–7.98] Adult
HLA-DQ8 (rs7454108) T 0.94 0.97 0.89 0.08 1.72 [0.93–3.18] Pediatric
0.20 1.37 [0.84–2.22] Adult
HLA-DQ4 (rs4713586) T 0.98 0.92 0.94 0.03 9.05 [1.18–69.50] Pediatric
0.03 3.71 [1.18–11.78] Adult
Genotype data for SNP (rs4639334) tagging -DQ7 haplotype was not present in the dataset and therefore was not available for the study
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adult patients with CD had one or more associated
autoimmune disorders in comparison to approxi-
mately 3 % in the general population [25–27]. This
may happen due to late diagnosis of CD and longer
duration of exposure to gluten in adults [25]. On the
other hand, early institution of gluten-free diet in
children patients may act as a protective factor
against development of another autoimmune disease
in pediatric CD [28].
It is noteworthy that already reported HLA-DQ haplo-
types emerged as the major genetic risk factor in both
pediatric and adult CD groups (Table 4) and confers
equal risk to both of these groups (Table 5). In addition
ANK3, an integral membrane protein controlling cyto-
skeleton, cell motility, proliferation and intestinal con-
traction, was the only other novel non-HLA marker
which was associated with both pediatric and adult CD
groups (Tables 2 and 3). Along with top HLA marker
(rs2854275-T), risk variants from ANK3 (rs4948256-A
among pediatric and rs10994257-T among adults) ex-
plains ~45 % of the CD cases. This finding reiterates ourTable 5 Comparative distribution of HLA-DQ haplotypes in
pediatric CD and adult CD groups








Prediction of DQ genotypes were done based on known tag SNPs originally
identified in Europeans. One individual from each group was dropped from
the study as genotype information for all tag SNPs were not present in the
final dataset for these two individualsprevious observation in a trans-ethnic study, where
ANK3 was identified in the same combined CD cohort
[18]. It is worthwhile to mention that ANK3 has been
shown to be associated with bipolar disorder and schizo-
phrenia [29–32]. Interestingly, a co-occurrence of bipo-
lar disorder and schizophrenia has been observed in
patients with CD [33–35]. Furthermore, approximately
10 % of patients with CD have some form of neuro-
logical disorders such as seizures, cognitive impairment,
migraine or other psychiatric illness [33, 34] However,
role if any, of ANK3 in occurrence of neurological and
psychological disorder in patients with CD warrant fur-
ther investigations. Contrary to two (HLA-DQ and
ANK3) shared genes, most of the other associated genes
in both pediatric and adult CD are notably different
from each other. Though these genes seem functionally
related and are present in similar pathways including cell
signalling, cell cycle regulation, inflammatory responses
and cellular metabolism (Additional file 2: Table S1).
The degree of risk for associated allelic variants with
pediatric CD is significantly different (higher degree of
odds ratio heterogeneity) from the allelic variants in the
adult CD groups (Additional file 2: Table S2). This may
signify that these genes with minor risk contributions are
specific to each of these two groups and might work in a
network with known susceptible genes for the onset of dif-
ferent clinical phenotypes. In the absence of literature on
the detailed function of these novel genes, their exact role
in age specific CD pathogenesis remains to be understood.
Of 39 known non-HLA CD loci [13], THEMIS, a gene
involved in T-cell development was observed to be associ-
ated with only adult CD group. Cis-eQTL evaluation of
the suggestive risk variants that we observed in the study,
indicated highly significant functional relevance of 11
(35.5 %) risk variants which were seen to alter the level of
gene expression at these loci (Additional file 2: Table S3).
Further, pathway and genetic interaction analysis
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be involved in inflammatory process and are functionally
related to the known 39 non-HLA CD loci (Additional file
2: Table S4). This novel comparative study identified sug-
gestive loci in each of these groups but needs follow-up
replication. In silico evidences of their effects on gene ex-
pression and involvement in integrated pathways in dis-
ease pathogenesis support their probable contribution.
Therefore, additional investigations across ethnic groups
and also functional validation are warranted.
Conclusions
Pediatric and adult CD seem to be a continuum of the dis-
ease entity with same HLA-DQ haplotypes and ANK3 be-
ing major genetic risk determinants. However, different
sets of minor risk conferring genetic loci with promising
functional involvement but which are present in a com-
mon network with other genes may determine the qu-
antitative disease heterogeneity between them. These,
preliminary findings warranted replication and fine map-
ping to confirm risk alleles.
Additional files
Additional file 1: Figure S1. QQ plots showing level of genomic
inflation in (a) Paediatric CD and (b) Adult CD groups in north Indian
population. Inflation was measured using 3016 independent, neutral-
reported variants present on the array (derived from reading and math
skills GWAS therefore unlikely to be confounded by the immune signal).
FigureS2. Manhattan plots showing association signals in (a) Paediatric
CD and (b) Adult CD in north Indian population. (DOCX 254 kb)
Additional file 2: Table S1. Functional profiles of the top non-HLA
association signals identified in Paediatric CD and Adult CD among north
Indians. Table S2. Test of heterogeneity (Breslow-Day test) for associated
SNPs in PaediatricCD and AdultCD groups. Table S3. cis-eQTL evaluation
of associated SNPs. Table S4. GRAIL analysis revealed seven genes with
significant (p <0.05) interaction with 39 known non-HLA coeliac
disease loci. These seven genes are from four loci identified in this
study. (DOCX 26 kb)
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